Xi Chen
Fujian University of Traditional Chinese Medicine(CN)Fujian Medical University(CN)Central South University(CN)Army Medical University(CN)Sun Yat-sen University(CN)Wenzhou Medical University(CN)First Affiliated Hospital of Wenzhou Medical University(CN)Tianjin Medical University Cancer Institute and Hospital(CN)Soochow University(CN)Liuzhou General Hospital(CN)Gansu University of Traditional Chinese Medicine(CN)Karachi Institute of Radiotherapy and Nuclear Medicine(PK)Second Affiliated Hospital of Soochow University(CN)Jiangsu Cancer Hospital(CN)Second Xiangya Hospital of Central South University(CN)Second Affiliated Hospital of Zhejiang University(CN)Union Hospital(CN)Institute of Radiotherapy and Nuclear Medicine(PK)Tianjin Medical University(CN)Zhejiang University(CN)Nanjing Medical University(CN)Chongqing Medical University(CN)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Lung Cancer Research Studies, Cytokine Signaling Pathways and Interactions, FOXO transcription factor regulation, PI3K/AKT/mTOR signaling in cancer
Most-Cited Works
- → Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial(2019)3,270 cited
- → Rationale for co-targeting IGF-1R and ALK in ALK fusion–positive lung cancer(2014)266 cited
- → Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial(2020)251 cited
- → Characteristics of Lung Cancers Harboring NRAS Mutations(2013)142 cited
- → The genomic landscape of Epstein-Barr virus-associated pulmonary lymphoepithelioma-like carcinoma(2019)125 cited
- → Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study